Abbott Laboratories (ABT) EVP Louis Morrone receives new stock and option awards

Rhea-AI Filing Summary

ABBOTT LABORATORIES executive Louis H. Morrone reported equity awards granted on February 24, 2026. He acquired an option to buy 63,561 Abbott shares at an exercise price of $0.00 per share and a grant of 15,418 common shares, both reported as direct ownership.

The 15,418-share award is performance-based restricted stock under the Abbott Laboratories 2017 Incentive Stock Program with a 3‑year term, where no more than one‑third can vest in any year and vesting depends on Abbott reaching a minimum return on equity target, and it allows shares to be withheld for taxes. The stock option, also under the 2017 Incentive Stock Program, was granted in a transaction exempt from Section 16 under Rule 16b‑3 and becomes exercisable in three equal annual installments of 21,187 shares on February 24, 2027, February 24, 2028, and February 24, 2029. The filing also notes an indirect holding of 12 Abbott shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Morrone Louis H.

Role EXECUTIVE VICE PRESIDENT

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	63,561	$0.00	--
Grant/Award	Common shares without par value	15,418	$0.00	--
holding	Common shares without par value	--	--	--

Holdings After Transaction: Option (right to buy) — 63,561 shares (Direct); Common shares without par value — 82,027 shares (Direct); Common shares without par value — 12 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,187 on February 24, 2027, 21,187 on February 24, 2028, and 21,187 on February 24, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrone Louis H.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		15,418(1)	A	$0	82,027	D
Common shares without par value								12(2)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(3)	$114.6	02/24/2026		A		63,561		02/24/2027	02/23/2036	Common Shares	63,561	$0	63,561	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 21,187 on February 24, 2027, 21,187 on February 24, 2028, and 21,187 on February 24, 2029.

	/s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Abbott Laboratories (ABT) executive Louis H. Morrone report in this Form 4?

Louis H. Morrone reported the acquisition of stock options and performance-based restricted stock awards in Abbott Laboratories. The filing shows new option and share grants under the 2017 Incentive Stock Program, along with a small indirect holding in the Abbott Laboratories Stock Retirement Trust.

How many stock options did Louis H. Morrone receive from Abbott Laboratories (ABT)?

Louis H. Morrone received an employee stock option covering 63,561 Abbott Laboratories shares at an exercise price of $0.00 per share. This option was granted under the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b‑3.

What are the vesting terms of Louis H. Morrone’s Abbott performance-based restricted stock award?

The performance-based restricted stock award of 15,418 Abbott shares has a three-year term. No more than one‑third of the award can vest in any one year, and vesting occurs only if Abbott reaches a minimum return on equity target, with shares eligible to be withheld for tax purposes.

When do Louis H. Morrone’s Abbott Laboratories stock options become exercisable?

The employee stock option becomes exercisable in three equal annual installments. Morrone can exercise 21,187 shares on February 24, 2027, another 21,187 shares on February 24, 2028, and the remaining 21,187 shares on February 24, 2029, according to the Form 4 footnotes.

What indirect Abbott Laboratories holdings are reported for Louis H. Morrone?

The filing reports an indirect holding of 12 Abbott Laboratories common shares in the Abbott Laboratories Stock Retirement Trust. This balance is stated as of February 24, 2026, and is classified as indirect ownership through a profit sharing trust in the Form 4 data.

Under which plan were Louis H. Morrone’s Abbott equity awards granted?

Both the performance-based restricted stock award and the employee stock option were granted under the Abbott Laboratories 2017 Incentive Stock Program. The option grant is described as a transaction exempt from Section 16 under Rule 16b‑3, reflecting standard equity compensation practices.